MINDCURE Announces Pre- and Post-Psychedelic Therapy Adaptogen Supplements, Defining New Product Category Post published:January 26, 2021 Post category:Press Release
Mind Cure Health Inc. Announces an Increase to Previously Announced Bought Deal Public Offering Post published:January 22, 2021 Post category:Press Release
Mind Cure Health Inc. Announces $10 Million Bought Deal Public Offering Post published:January 21, 2021 Post category:Press Release
Mind Cure Signs LOI to Acquire an Ownership Interest in Psychedelic Treatment Center ATMA, Selected by Section 56 Exempt Patient for Psilocybin Therapy Post published:January 12, 2021 Post category:Press Release
Mind Cure Announces Build-Out of Digital Therapeutics, iSTRYM: A Technology Platform for Mental Wellness Optimization & Psychedelic Research Post published:January 6, 2021 Post category:Press Release
Mind Cure Announces Retail Roll Out of Nootropics Lineup Across North America with Body Energy Club Post published:December 31, 2020 Post category:Press Release
Mind Cure Announces Novel Supplement Product to Address Teen Wellness Post published:December 29, 2020 Post category:Press Release
Mind Cure Moves into Psychedelic Assisted Therapy with British Columbia Location Offering Ketamine and Psilocybin Therapy Post published:December 10, 2020 Post category:Press Release
Mind Cure Announces its Research Program with Psychedelic Compounds Post published:December 8, 2020 Post category:Press Release
Mind Cure Announces Eligibility for DTC Trading Post published:December 2, 2020 Post category:Press Release